Advances in adult MASH care could be ‘catalyst’ for pediatrics

Coverage, in order

1. 1d ago
   
   Healio indie

   Advances in adult MASH care could be ‘catalyst’ for pediatrics

   The recent FDA approvals of pharmacologic therapies for metabolic dysfunction-associated steatohepatitis were “breakthrough moments in history” for a disease whose management had mostly relied on lifestyle interventions. However, the two drugs that drastically changed the treatment of MASH in…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.